329 related articles for article (PubMed ID: 21924649)
1. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.
DeGraff DJ; Cates JM; Mauney JR; Clark PE; Matusik RJ; Adam RM
Urol Oncol; 2013 Aug; 31(6):802-11. PubMed ID: 21924649
[TBL] [Abstract][Full Text] [Related]
2. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
4. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.
Reddy OL; Cates JM; Gellert LL; Crist HS; Yang Z; Yamashita H; Taylor JA; Smith JA; Chang SS; Cookson MS; You C; Barocas DA; Grabowska MM; Ye F; Wu XR; Yi Y; Matusik RJ; Kaestner KH; Clark PE; DeGraff DJ
Am J Pathol; 2015 May; 185(5):1385-95. PubMed ID: 25907831
[TBL] [Abstract][Full Text] [Related]
5. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
6. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105
[TBL] [Abstract][Full Text] [Related]
7. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.
Tsai MC; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Chan TC; Liang PI; Yeh BW; Wu WJ; Lim SW; Li CF
Oncotarget; 2016 Nov; 7(48):78918-78931. PubMed ID: 27793038
[TBL] [Abstract][Full Text] [Related]
8. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
[TBL] [Abstract][Full Text] [Related]
9. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
[TBL] [Abstract][Full Text] [Related]
10. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
11. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
12. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
13. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas.
Ohlsson G; Moreira JM; Gromov P; Sauter G; Celis JE
Mol Cell Proteomics; 2005 Apr; 4(4):570-81. PubMed ID: 15734831
[TBL] [Abstract][Full Text] [Related]
16. Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
Mehus AA; Bergum N; Knutson P; Shrestha S; Zhou XD; Garrett SH; Sens DA; Sens MA; Somji S
PLoS One; 2020; 15(8):e0237976. PubMed ID: 32822399
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome.
Mylona E; Giannopoulou I; Diamantopoulou K; Bakarakos P; Nomikos A; Zervas A; Nakopoulou L
Eur J Surg Oncol; 2009 Feb; 35(2):197-201. PubMed ID: 18513919
[TBL] [Abstract][Full Text] [Related]
18. Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression.
Jóźwicki W; Brożyna AA; Siekiera J
Int J Mol Sci; 2014 Sep; 15(9):16069-82. PubMed ID: 25216339
[TBL] [Abstract][Full Text] [Related]
19. FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines.
Warrick JI; Walter V; Yamashita H; Chung E; Shuman L; Amponsa VO; Zheng Z; Chan W; Whitcomb TL; Yue F; Iyyanki T; Kawasawa YI; Kaag M; Guo W; Raman JD; Park JS; DeGraff DJ
Sci Rep; 2016 Dec; 6():38531. PubMed ID: 27924948
[TBL] [Abstract][Full Text] [Related]
20. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.
Hagikura M; Murakumo Y; Hasegawa M; Jijiwa M; Hagiwara S; Mii S; Hagikura S; Matsukawa Y; Yoshino Y; Hattori R; Wakai K; Nakamura S; Gotoh M; Takahashi M
Pathol Int; 2010 Nov; 60(11):735-43. PubMed ID: 20946523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
